相似文献
1
Abnormalities in signaling pathways in diabetic nephropathy.
Expert Rev Endocrinol Metab. 2010;5(1):51-64. doi: 10.1586/eem.09.70.
2
New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy.
Rev Endocr Metab Disord. 2008 Dec;9(4):245-54. doi: 10.1007/s11154-008-9100-6.
3
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Acta Pharm Sin B. 2021 Sep;11(9):2749-2767. doi: 10.1016/j.apsb.2020.12.020. Epub 2021 Feb 2.
4
Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.
Diabetes. 2009 Feb;58(2):469-77. doi: 10.2337/db08-1328. Epub 2008 Nov 18.
5
Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
Curr Diabetes Rev. 2008 Feb;4(1):39-45. doi: 10.2174/157339908783502370.
6
Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Eur J Pharmacol. 2018 Apr 5;824:170-178. doi: 10.1016/j.ejphar.2018.02.009. Epub 2018 Feb 11.
7
Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis.
Autophagy. 2015;11(7):1130-45. doi: 10.1080/15548627.2015.1049799.
9
Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.
Nefrologia. 2015;35(2):131-8. doi: 10.1016/j.nefro.2015.05.013. Epub 2015 Jun 23.
10
A meta-analysis of the effects of endothelial nitric oxide synthase 4ba polymorphism on renal interstitial fibrosis in diabetic nephropathy.
Ann Palliat Med. 2021 Jan;10(1):633-645. doi: 10.21037/apm-20-2585.
引用本文的文献
1
Circular RNAs and the regulation of gene expression in diabetic nephropathy (Review).
Int J Mol Med. 2024 May;53(5). doi: 10.3892/ijmm.2024.5368. Epub 2024 Mar 22.
2
The Role of the Epidermal Growth Factor Receptor in Diabetic Kidney Disease.
Cells. 2022 Oct 28;11(21):3416. doi: 10.3390/cells11213416.
3
Comparative co-expression analysis of RNA-Seq transcriptome revealing key genes, miRNA and transcription factor in distinct metabolic pathways in diabetic nerve, eye, and kidney disease.
Genomics Inform. 2022 Sep;20(3):e26. doi: 10.5808/gi.22029. Epub 2022 Sep 30.
4
Ameliorates Streptozotocin-Induced Diabetic Nephropathy through Antioxidant and Anti-Inflammatory Pathways.
Molecules. 2022 Aug 5;27(15):4985. doi: 10.3390/molecules27154985.
5
Identification of CCL19 as a Novel Immune-Related Biomarker in Diabetic Nephropathy.
Front Genet. 2022 Feb 9;13:830437. doi: 10.3389/fgene.2022.830437. eCollection 2022.
6
The Wnt Signaling Pathway in Diabetic Nephropathy.
Front Cell Dev Biol. 2022 Jan 4;9:701547. doi: 10.3389/fcell.2021.701547. eCollection 2021.
7
Nucleoporin 160 (NUP160) inhibition alleviates diabetic nephropathy by activating autophagy.
Bioengineered. 2021 Dec;12(1):6390-6402. doi: 10.1080/21655979.2021.1968777.
8
TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy.
Acta Diabetol. 2021 Dec;58(12):1587-1594. doi: 10.1007/s00592-021-01766-y. Epub 2021 Jun 28.
9
Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy.
Diabetes. 2021 Feb;70(2):562-576. doi: 10.2337/db20-0660. Epub 2020 Nov 25.
10
Pyrrolidine dithiocarbamate reduces alloxan-induced kidney damage by decreasing nox4, inducible nitric oxide synthase, and metalloproteinase-2.
Naunyn Schmiedebergs Arch Pharmacol. 2020 Oct;393(10):1899-1910. doi: 10.1007/s00210-020-01906-1. Epub 2020 May 21.
本文引用的文献
1
Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria.
J Am Soc Nephrol. 2009 Sep;20(9):1997-2008. doi: 10.1681/ASN.2009010019. Epub 2009 Jul 23.
2
Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.
Diabetes. 2009 Sep;58(9):2109-18. doi: 10.2337/db08-0895. Epub 2009 Jul 8.
3
Nitric oxide inhibits glomerular TGF-beta signaling via SMOC-1.
J Am Soc Nephrol. 2009 Sep;20(9):1963-74. doi: 10.1681/ASN.2008060653. Epub 2009 Jul 2.
4
Abnormal angiogenesis in diabetic nephropathy.
Diabetes. 2009 Jul;58(7):1471-8. doi: 10.2337/db09-0119.
5
Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb.
Mol Cell Biol. 2009 Jul;29(14):3991-4001. doi: 10.1128/MCB.00165-09. Epub 2009 May 18.
6
The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.
Biochem Biophys Res Commun. 2009 Jul 10;384(4):471-5. doi: 10.1016/j.bbrc.2009.04.136. Epub 2009 May 5.
7
The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability.
Am J Physiol Renal Physiol. 2009 Jul;297(1):F85-94. doi: 10.1152/ajprenal.90642.2008. Epub 2009 May 6.
8
Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation.
Nephrol Dial Transplant. 2009 Sep;24(9):2645-55. doi: 10.1093/ndt/gfp204. Epub 2009 May 6.
9
The pathogenic role of Notch activation in podocytes.
Nephron Exp Nephrol. 2009;111(4):e73-9. doi: 10.1159/000209207. Epub 2009 Mar 17.
10
Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy.
Cell Cycle. 2009 Feb 15;8(4):567-72. doi: 10.4161/cc.8.4.7659. Epub 2009 Feb 18.
Zotero 插件